Search the Newsreel

Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Beats Estimates By $4.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced strong quarterly earnings, beating analyst estimates by $4.13 EPS with revenue reaching $4.29 billion, exceeding forecasts. This performance was driven by significant sales growth in products like Dupixent, EYLEA HD, and Libtayo, despite a decline in legacy EYLEA sales due …

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $737.00

Royal Bank of Canada raised its price target for Regeneron Pharmaceuticals (REGN) to $737 from $696, maintaining a "sector perform" rating. This adjustment follows Regeneron's strong quarterly results, which saw EPS and revenue exceed analyst expectations, leading to a 3.5% increase in share price. …

Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

Regeneron Pharmaceuticals (NASDAQ: REGN) is facing a securities class action lawsuit due to alleged false and misleading statements concerning a failed Phase 3 clinical trial for a melanoma treatment. The lawsuit, initiated by Hagens Berman, represents investors who purchased stock between August 1, 2025, …

REGENERON PHARMACEUTICALS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $772 FROM $769

Truist Securities has increased its target price for Regeneron Pharmaceuticals Inc (REGN.O) from $769 to $772. This adjustment reflects an updated outlook from the financial institution regarding the pharmaceutical company's valuation. The news was reported by Reuters.

Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $750 From $700, Maintains Equalweight Rating

Wells Fargo has adjusted its price target for Regeneron Pharmaceuticals (REGN) to $750, up from the previous $700, while maintaining an Equalweight rating on the stock. This update reflects a re-evaluation of the company's financial outlook by the analyst firm. The article also notes …

BMO Capital Adjusts PT on Regeneron Pharmaceuticals to $800 From $730, Maintains Outperform Rating

BMO Capital has increased its price target for Regeneron Pharmaceuticals (REGN) from $730 to $800, while reiterating an Outperform rating. This adjustment reflects continued positive analyst sentiment towards the pharmaceutical company. The article notes several other firms also recently raised their price targets for …

Raymond James Adjusts PT on Regeneron Pharmaceuticals to $911 From $902, Keeps Outperform Rating

Raymond James has increased its price target for Regeneron Pharmaceuticals (NASDAQ: REGN) to $911 from $902, while maintaining an Outperform rating on the stock. This adjustment reflects the firm's positive outlook on the pharmaceutical company's future performance.

RYTM|Rhythm Pharmaceuticals Inc|Price:105.800|Chg%:-0.730

Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in …

Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Before September 14, 2026 - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who suffered losses between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its …

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals reported strong second-quarter 2026 financial results, with global net product revenues of $1,172 million, a 74% increase from Q2 2025, primarily driven by their TTR franchise. Despite revising full-year 2026 TTR net product revenue guidance downwards slightly due to a normalization of …

REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026

SueWallSt is notifying investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a class action lawsuit filed on behalf of shareholders who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding the Phase III Fianlimab-Libtayo …

Regeneron Pharmaceuticals Crushes Q2 2026 Profit Estimates

Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q2 2026 results, with Non-GAAP EPS of $14.29 significantly beating estimates and revenue reaching $4.29 billion, a 17% increase year-over-year. The impressive performance was largely driven by its blockbuster drug Dupixent, which saw revenue surge by 38%, highlighting …

Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic

Regeneron's Q2 saw its largest quarterly revenue increase since the pandemic, primarily driven by booming Dupixent sales which reached $6 billion globally. This growth, fueled by label expansions including a key COPD approval, led to a 38% year-over-year increase for Dupixent. Regeneron also reported …

Regeneron (REGN) Stock Looks Undervalued Despite A 28% Gain And Legal Risk

Regeneron Pharmaceuticals (REGN) has seen a 28.2% return over the past year but still appears undervalued according to several metrics, trading below the industry P/E average. Despite this, the company faces significant legal and pipeline risks, including a securities class action related to a …

Regeneron Pharmaceuticals Releases Q2 2026 Financial Results

Regeneron Pharmaceuticals reported strong Q2 2026 financial results, with non-GAAP earnings per share of $14.29, significantly beating the $10.26 estimate, and revenue of $4.29 billion, surpassing the $3.82 billion estimate. The company's blockbuster drug Dupixent was a major driver, generating $6.00 billion in revenue …

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron Pharmaceuticals exceeded Wall Street's second-quarter revenue and profit estimates, driven by robust demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, in partnership with Sanofi, surged 38% to approximately $6 billion, while …

Regeneron Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise

Regeneron Pharmaceuticals reported an increase in adjusted earnings and revenue for the second quarter of 2026. The company saw its adjusted EPS reach $14.29 per share against an estimated $10.16, and revenue hit $4.29 billion, surpassing the FactSet estimate of $3.82 billion. This positive …

Regeneron stock rises after strong Q2 2026 beat (REGN:NASDAQ)

Regeneron Pharmaceuticals (REGN) shares rose in premarket trading after reporting strong Q2 2026 results that surpassed Street estimates. This beat was primarily driven by higher sales of its new high-dose Eylea eye therapy. The company also saw increased revenues from its collaboration with Sanofi, …

Regeneron shares rise 3% on beating estimates as Dupixent sales surge 38%

Regeneron Pharmaceuticals Inc. reported strong second-quarter results, surpassing analyst expectations for both earnings per share and revenue. The company's impressive performance was fueled by significant sales growth from key products like Dupixent, EYLEA HD, and Libtayo. Following the positive earnings release and updated guidance …

Regeneron: Q2 Earnings Snapshot

This article provides a brief snapshot of Regeneron's Q2 earnings. No specific financial details are available in the provided content. The title suggests a focus on the company's fiscal performance for the second quarter.

Regeneron Pharma: About 50 Product Candidates in Clinical Development >REGN

Regeneron Pharmaceuticals currently has approximately 50 product candidates in clinical development, according to the company. This substantial pipeline highlights Regeneron's focus on research and development in the pharmaceutical industry.

Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results

Regeneron Pharmaceuticals (NASDAQ:REGN) surpassed second-quarter earnings and revenue expectations, driven by strong growth in its commercial portfolio, particularly Dupixent sales. The company reported adjusted earnings of $14.29 per share and revenue of $4.29 billion, exceeding analyst forecasts. Following these results, Regeneron updated its full-year …

Regeneron (REGN) Stock Looks Cheap On Earnings Yet Mixed Elsewhere

Regeneron Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:REGN) 2026-07-30

Regeneron Pharmaceuticals Inc. (REGN) reported strong Q2 2026 results with a 17% increase in total revenue to $4.3 billion and an 11% rise in non-GAAP diluted EPS, driven by record sales of Dupixent and EYLEA HD. The company highlighted its deep pipeline, including advancing …

Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims Regeneron made positive statements while concealing material adverse facts about its Phase III …

REGN Stockholders Have Rights – If You Lost Money Investing

Robbins LLP reminds investors that a securities class action has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for allegedly misleading investors regarding its Phase 3 Fianlimab-Libtayo clinical trial. The lawsuit claims Regeneron failed to disclose flaws in the study's statistical assumptions and that …

Is Vertex Pharmaceuticals (VRTX) Cheap On Its AbCellera Collaboration News?

Vertex Pharmaceuticals (VRTX) recently announced a collaboration with AbCellera Biologics for autoimmune disease therapies, leading to fresh attention on its stock. Despite a 13.09% return over 90 days and 142.16% over five years, the stock is trading at a meaningful discount to intrinsic estimates …

Regeneron earnings in focus: Can Dupixent offset Eylea woes?

Regeneron Pharmaceuticals Inc. is set to release its second-quarter earnings, with investors focused on whether the strong performance of Dupixent can mitigate the challenges faced by the Eylea franchise due to competition. While Wall Street maintains a bullish outlook with a high mean price …

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm

Levi & Korsinsky, LLP has alerted stockholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a pending securities class action lawsuit. The lawsuit alleges that Regeneron made misleading statements regarding a Phase III melanoma study, leading to a significant stock price decline. Investors who suffered …

REGN Court Deadline: Regeneron Investor Deadline in

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) due to stock drops following alleged misleading statements about its Phase III Fianlimab-Libtayo clinical trial. Investors have until September 14, 2026, to apply for lead plaintiff status. The lawsuit …

ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175

This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how …

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements about its Phase …

Regeneron Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Regeneron Pharmaceuticals (NASDAQ: REGN) had approximately 15,473 employees worldwide as of March 2026, marking a 14.8% growth since 2023 but a 1.0% decrease year-over-year in 2026. The company is actively hiring, with 972 active job postings in 2026, a 34.4% increase from 2025. The …

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of Regeneron Pharmaceuticals Inc. (REGN) rose by 4.20% on Tuesday, closing at $695.18. Despite these daily gains and the broader market's positive performance, with the S&P 500 and Dow Jones also increasing, the company's stock underperformed when compared to its competitors. This marked …

REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), announcing a lead plaintiff deadline of September 14, 2026, for a securities class action. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading …

REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors. The lawsuit alleges that Regeneron misled investors about the success of its Phase III Fianlimab-Libtayo clinical trial, leading to significant stock …